• About
• Links
• Contact
• Sitemap
• 

Womens Health 2009: Worldwide Prescription Drug Markets

Women’s health encompasses all different areas of medicine and it would be a monumental task to address all of the areas that affect women. This report will concentrate on disorders that affect the female reproductive system and other disorders where there is at least a 70% preponderance of women affected by the disorder. The worldwide prescription drug market for women’s health consists of total manufacturers’ revenues from the following product categories:

• Autoimmune diseases
• Cancer
• Gynecological and Sexually Transmitted Diseases
• Hormones
• Osteoporosis
• Urinary Disorders

Women's Health 2009: Worldwide Prescription Drug Markets tackles the women's health pharmaceutical market. Revenues from these segments are not reported in total, as certain segments affect both men and women. The analysis and market data in this report estimate revenues associated with therapeutics for women only. Segmentation within each category is by major drug type and by geographic region (U.S., Europe, Japan, ROW). All market data pertain to the U.S. market at the manufacturers’ level. Data are expressed in current U.S. dollars. The base year for data was 2007. forecast data are provided for each of the years 2009 through 2013. Historical, base year, and forecast data are provided for each market segment. Market shares are provided for each market segment for the 2007 base year.

In addition to market data, the report contains extensive product pipeline information, competitor profiles, and discussions of the major industry issues and trends shaping the market.

The information and analysis presented in this report are based on an extensive survey of senior management in the prescription women’s health drug industry. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with over 40 industry executives and product managers to validate and obtain expert opinion on current and future trends in the women’s health industry. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as in formulating market projections.

Table of Contents

TABLE OF CONTENTSCHAPTER ONE:EXECUTIVE SUMMARY

• Scope and Methodology
• Size and Growth of the Market
• Total Market Size and Forecast
• Market Outlook

CHAPTER TWO: INTRODUCTION AND OVERVIEW

• History of Women’s Health
• Female Reproductive System
• Hormone Regulation
• Market Trends
  • Women’s Health Initiative
  • Women’s Health Office Act of 2007
  • Perimenopausal Use of Contraceptives
  • Insurance Coverage for Contraceptives
  • Oral Contraceptives in Japan
  • Ovarian Cancer Test
  • Estrogen Labeling
  • Osteoporosis Drug Opportunities in Asia
  • Women’s Healthcare Access
• Demographics

CHAPTER THREE: AUTOIMMUNE DISEASES

• Overview
• Prevalence
• Chronic Fatigue Syndrome
• Treatment
• Fibromyalgia
• Treatment
• Rheumatoid Arthritis
• Treatment
• Scleroderma
• Treatment
• Sjogren’s Syndrome
• Treatment
• Systemic Lupus Erythematosus
• Treatment
• Market Size and Growth
• Geographical Market Analysis
• Research and Development
  • Ampligen
  • Actemra
  • Apilimod
  • Arcoxia
  • Cimza
  • Denosumab
  • INCBO18424
  • Interleukin (IL-1)
  • LymphoStat-B
  • Milnacipran
  • Prestara
  • Riquent
  • Veldona
• Competitive Market

CHAPTER FOUR: CANCER

• Overview
• Incidence and Mortality
• Breast Cancer
• Overview
• Treatment
• Cervical Cancer
• Overview
• Treatment
• Endometrial Cancer
• Overview
• Treatment
• Ovarian Cance
• Overview
• Treatment
• Vaginal Cancer
• Overview
• Treatment
• Market Size and Growth
• Geographical Market Analysis
• Research and Development
• Advexin
• Alvespimycin
• Arzoxifene
• Avastin
• Axtinib
• Cervarix
• Herceptin
• Karenitecin
• Pazopanib
• Pertuzumab
• Tykerb
• Yondeli
• Competitive Market

CHAPTER FIVE: GYNECOLOGICAL INFECTIONS AND SEXUALLY TRANSMITTED DISEASES

• Overview
• Incidence and Prevalence
• AIDS
  • Overview
  • Treatment
  • Agenerase
  • Aptivus
  • Combivir
  • Crixivan
  • Entriva
  • Fortovase
  • Fuzeon
  • Hivid
  • Intelence
  • Invirase
  • Isentress
  • Kaletra
  • Kivexa
  • Lexiva
  • Prezista
  • Rescriptor
  • Reyataz
  • Selzentry
  • Sustiva
  • Trizivir
  • Truvada
  • Viracept
  • Viramune
• Bacterial Vaginosis
• Overview
• Treatment
• Cervical Dysplasia
• Overview
• Treatment
• Chlamydia
• Overview
• Treatment
• Condyloma Acuminata
• Overview
• Treatment
• Aldara
• Alferon N Injection
• Condylox
• Gardasil
• Genital Herpes
• Overview
• Treatment
• Zovirax
• Gonorrhea
• Overview
• Treatment
• Hepatitis
• Overview
• Treatment
• Baraclude
• Pelvic Inflammatory Disease
• Overview
• Treatment
• Syphilis
• Overview
• Treatment
• Toxic Shock Syndrome
• Overview
• Treatment
• Yeast Infections
• Overview
• Treatment
• Market Size and Growth
• Geographical Market Analysis
• Research and Development
  • Ampligen
  • Bevirimat
  • Boceprevir
  • Clevudine
  • Elvitegravir
  • GS 9137
  • Hepaconda
  • IC41
  • IDX899
  • Loctero
  • R7128
  • RDEA806
  • SPO1A
  • Telaprevir
  • TMC278
  • Vicriviroc
  • VRX496
• Competitive Market

CHAPTER SIX: HORMONE-RELATED DISORDERS

• Overview
• Statistics
• Contraception
• Overview
• Treatment
• Oral Contraceptives
• Depo-Provera
• Birth Control Patch
• Vaginal Ring
• Emergency Contraception and Early Option
• Implant
• IUD
• Endometriosis
• Overview
• Treatment
• Fibroids
• Overview
• Treatment
• Infertility
• Overview
• Treatment
• Menopause
• Overview
• Treatment
• Menstrual Disorders
• Amenorrhea
• Treatment
• Dysmenorrhea
• Treatment
• Sexual Dysfunction
• Overview
• Treatment
• Market Size and Growth
• Geographical Market Analysis
• Research and Development
• Alista
• LibiGel
• NOMAC/E2
• Ophena
• Org 36286
• Competitive Market

CHAPTER SEVEN: OSTEOPOROSIS

• Overview
• Prevalence
• Prevention
• Treatment
• Market Size and Growth
• Geographical Market Analysis
• Research and Development
• Arzoxifene
• Denosumab
• Fablyn
• MK-0822 (Odanacatib)
• Preos
• SUN E3001
• Viviant
• Competitive Market

CHAPTER EIGHT: URINARY BLADDER DISORDERS

• Overview
• Incidence and Prevalence
• Cystitis
• Overview
• Treatment
• Incontinence
• Overview
• Treatment
• Overactive Bladder
• Treatment
• Alternative Treatments
• Interstitial Cystitis
• Overview
• Treatment
• Market Size and Growth
• Geographical Market Analysis
• Research and Development
• Oxybutynin Gel
• Anturol
• PSD503
• Competitive Market

CHAPTER NINE: WORLD MARKET SUMMARY

• Overview
• Total Market Size and Forecast
• Market Analysis

CHAPTER TEN:CORPORATE PROFILES AND ANALYSIS

• Overview

APPENDIX: COMPANY DIRECTORY: MAJOR SUPPLIERS

TABLE OF EXHIBITSCHAPTER ONE: EXECUTIVE SUMMARY

• Table 1-1: The World Market Women’s Disorders 2006-2013
• Figure 1-1: The World Market Women’s Disorders 2006-2013

CHAPTER TWO: INTRODUCTION AND OVERVIEW

• Table 2-1: World Life Expectancy at Birth in Selected Countries by Sex, 2007
• Figure 2-1: Female Advantage in Life Expectancy at Birth in Selected Countries, 2007 (Difference, in Years, between Females and Males)
• Table 2-2: World Population Growth, by Total World Population and Selected Country or Regions and Selected Characteristics
• Figure 2-2: World Population Growth by Sex 2000, 2005, 2010, 2020, 2025 (in millions)
• Figure 2-3: United States Population Growth by Sex 2000, 2005, 2010, 2020, 2025 (in millions)
• Figure 2-4: Five Major European Countries* Population Growth by Sex 2000, 2005, 2010, 2020, 2025 (in millions)
• Figure 2-5: Japan Population Growth by Sex 2000, 2005, 2010, 2020, 2025 (in millions)
• Table 2-3: World Female Population Growth by Selected Country or Regions and Selected Age Group
• Figure 2-6: World Female Population Growth by Selected Age Group 2000, 2005, 2010, 2020, 2025 (in millions)
• Figure 2-7: United States Female Population Growth by Selected Age Group 2000, 2005, 2010, 2020, 2025 (in millions)
• Figure 2-8: Five Major European Countries* Female Population Growth by Selected Age Group 2000, 2005, 2010, 2020, 2025 (in millions)
• Figure 2-9: Japan Female Population Growth by Selected Age Group 2000, 2005, 2010, 2020, 2025 (in millions)

CHAPTER THREE: AUTOIMMUNE DISEASES

• Table 3-1: Estimated Female Prevalence of Autoimmune Diseases by Type and Geographical Distribution, Estimated 2008
• Table 3-2: The World Market for Autoimmune Disease Drugs for Women 2006-2013
• Figure 3-1: The World Market for Autoimmune Disease Drugs for Women 2006-2013
• Table 3-3: The World Market for Autoimmune Disease Drugs for Women by Disease Type 2006-2013
• Figure 3-4: The World Market for Autoimmune Disease Drugs for
• Table 3-4 Women, Revenues by Disease Type 2006-2013
• Figure 3-3: The World Market for Autoimmune Disease Drugs for
• Figure 3-4: The World Market for Autoimmune Disease Drugs for Women, Market Share by Disease Type 2013
• Table 3-8: The World Market for Autoimmune Disease Drugs for
• Women Market Analysis by Region/Country, 2008
• Figure 3-5: The World Market for Autoimmune Disease Drugs for Women Market Analysis by Region/Country, 2008
• Table 3-5 Select Products in Development for Chronic Fatigue Syndrome 2008
• Table 3-6: Select Products in Development for Fibromyalgia 2008
• Table 3-7: Select Products in Development for Rheumatoid Arthritis 2008
• Table 3-8: Products in Development for Sjogren’s Syndrome, 2008
• Table 3-9: Products in Development for Systemic Lupus Erythematosus 2008
• Table 3-6: The World Market for Autoimmune Disease Drugs for Women Revenues and Market Share by Supplier 2008
• Figure 3-10: The World Market for Autoimmune Disease Drugs for Women Market Share by Leading Supplier 2008

CHAPTER FOUR: CANCER

• Table 4-1: Estimated Incidence of Female Cancers and Mortality by Type and Geographical Distribution, Estimated 2008
• Table 4-2: The World Market for Cancer Drugs for Women 2006-2013
• Figure 4-1: The World Market for Cancer Drugs for Women 2006-2013
• Table 4-3: The World Market for Cancer Drugs for Women by Disease Type 2006-2013
• Figure 4-2: The World Market for Cancer Drugs for Women, Revenues by Cancer Type 2006-2013
• Figure 4-3: The World Market for Cancer Drugs for Women, Market Share by Cancer Type 2008
• Figure 4-4: The World Market for Cancer Drugs for Women, Market Share by Cancer Type 2013
• Table 4-4: The World Market for Cancer Drugs for Women Market Analysis by Region/Country, 2008
• Figure 4-5: The World Market for Cancer Drugs for Women Market Analysis by Region/Country, 2008
• Table 4-5: Select Products in Development for Breast Cancer 2008
• Table 4-6: Select Products in Development for Cervical Cancer 2008
• Table 4-7: Select Products in Development for Endometrial Cancer 2008
• Table 4-8: Select Products in Development for Ovarian Cancer 2008
• Table 4-9: Select Products in Development for Vaginal Cancer, 2008
• Table 4-6: The World Market for Cancer Drugs for Women Revenues and Market Share by Supplier 2008
• Figure 4-10: The World Market for Cancer Drugs for Women MarketShare by Leading Supplier 2008

CHAPTER FIVE: GYNECOLOGICAL INFECTIONS AND SEXUALLY TRANSMITTED DISEASES

• Table 5-1: Estimated Female Incidence and Prevalence Gynecological and Sexually Transmitted Diseases by Type and Geographical Distribution, 2007/2008
• Table 5-2: Gynecological and Sexually Transmitted Diseases Related Epidemiologic Data, Five Year Average 2007/2008 Average
• Table 5-3: The World Market for Gynecological Infections and Sexually Transmitted Diseases for Women 2006-2013
• Figure 5-1: The World Market for Gynecological Infections and SexuallyTransmitted Diseases for Women 2006-2013
• Table 5-4: The World Market for Gynecological Infections and Sexually Transmitted Diseases for Women by Disease Type 2006-2013
• Figure 5-2: The World Market for Gynecological Infections and SexuallyTransmitted Diseases for Women, Revenues by Disease Type 2006-2013
• Figure 5-3: The World Market for Gynecological Infections and SexuallyTransmitted Diseases for Women, Market Share by Disease Type 2008
• Figure 5-4: The World Market for Gynecological Infections and SexuallyTransmitted Diseases for Women, Market Share by Disease Type 2013
• Table 5-5: The World Market for Gynecological Infections and Sexually Transmitted Diseases for Women Market Analysis by Region/Country, 2008
• Figure 5-5: The World Market for Gynecological Infections and Sexually Transmitted Diseases for Women Market Analysis by Region/Country, 2008
• Table 5-6: Select Products in Development for AIDS/HIV 2008
• Table 5-7: Select Products in Development for Cervical Dysplagia 2008
• Table 5-8: Select Products in Development for Condyloma Acumenta 2008
• Table 5-9: Select Products in Development for Genital Herpes 2008
• Table 5-10: Select Products in Development for Hepatitis, 2008
• Table 5-6: The World Market for Gynecological Infections and Sexually Transmitted Diseases for Women Revenues and Market Share by Supplier 2008
• Figure 5-11: The World Market for Gynecological Infections and Sexually Transmitted Diseases for Women Market Share by Leading Supplier 2008

CHAPTER SIX: HORMONE-RELATED DISORDERS

• Table 6-1: Estimated World and U.S. Female Incidence and Prevalence of Hormone-Related Disorders and Indications by Type, Five Year Average 2007/2008
• Table 6-2: Estimated World and U.S. Contraceptive Use by Method, Five Year Average 2007/2008
• Table 6-3: Selected Oral Contraceptives Available 2007/2008
• Table 6-4: Selected Hormone Replacement Therapies
• Table 6-5: The World Market for Hormone-related Disorders for Women, 2006-2013
• Figure 6-1: The World Market for Hormone-related Disorders for Women 2006-2013
• Table 6-6: The World Market for Hormone-related Disorders for Women by Disorder Type 2006-2013
• Figure 6-2: The World Market for Hormone-related Disorders for Women, Revenues by Disorder Type 2006-2013
• Figure 6-3: The World Market for Hormone-related Disorders for Women, Market Share by Disorder Type 2008
• Figure 6-4: The World Market for Hormone-related Disorders for Women, Market Share by Disorder Type 2013
• Table 6-7: The World Market for Hormone-related Disorders for Women Market Analysis by Region/Country, 2008
• Figure 6-5: The World Market for Hormone-related Disorders forWomen Market Analysis by Region/Country, 2008
• Table 6-8: Select Products in Development for Oral Contraceptives 2008
• Table 6-9: Select Products in Development for Endometriosis 2008
• Table 6-10: Select Products in Development for Infertility 2008
• Table 6-11: Select Products in Development for Menopause 2008
• Table 6-12: Select Products in Development for Menstrual Disorders 2008
• Table 6-13: Select Products in Development for Sexual Dysfunction 2008
• Table 6-14: The World Market for Hormone-related Disorders for Women Revenues and Market Share by Supplier 2008
• Figure 6-6: The World Market for Hormone-related Disorders for Women Market Share by Leading Supplier 2008

CHAPTER SEVEN: OSTEOPOROSIS

• Table 7-1: Estimated Female Prevalence of Osteoporosis by Type and Geographical Distribution, Average 2007/2008
• Table 7-2: The World Market for Osteoporosis Treatments for Women 2006-2013
• Figure 7-1: The World Market for Osteoporosis Treatments for Women 2006-2013
• Table 7-3: The World Market for Osteoporosis Treatments forWomen Market Analysis by Region/Country, 2008
• Figure 7-2: The World Market for Osteoporosis Treatments for Women Market Analysis by Region/Country, 2008
• Table 7-4: Select Products in Development for Osteoporosis Drugs 2008
• Table 7-5: The World Market for Osteoporosis Treatments for Women Revenues and Market Share by Supplier 2008
• Figure 7-3: The World Market for Osteoporosis Treatments for Women Market Share by Leading Supplier 2008

CHAPTER EIGHT: URINARY BLADDER DISORDERS

• Table 8-1: Estimated Female Incidence and Prevalence of Urinary Bladder Disorders by Type and Geographical Distribution, Average 2007/2008
• Table 8-2: Medications That Can Affect Urination
• Table 8-3: The World Market for Urinary Bladder Disorders for Women 2006-2013
• Figure 8-1: The World Market for Urinary Bladder Disordersfor Women 2006-2013
• Table 8-4: The World Market for Urinary Bladder Disorders for Women by Disease Type 2006-2013
• Figure 8-2: The World Market for Urinary Bladder Disorders for Women, Revenues by Disease Type 2006-2013
• Figure 8-3: The World Market for Urinary Bladder Disorders for Women, Market Share by Disease Type 2008
• Figure 8-4: The World Market for Urinary Bladder Disorders for Women, Market Share by Disease Type 2013
• Table 8-5: The World Market for Urinary Bladder Disorders for Women Market Analysis by Region/Country, 2008
• Figure 8-5: The World Market for Urinary Bladder Disorders for Women Market Analysis by Region/Country, 2008
• Table 8-6: Select Products in Development for Urinary Disorders 2008
• Table 8-7: The World Market for Urinary Bladder Disorders for Women Revenues and Market Share by Supplier 2008
• Figure 8-6: The World Market for Urinary Bladder Disorders for Women Market Share by Leading Supplier 2008

CHAPTER NINE: WORLD MARKET SUMMARY

• Table 9-1: The World Market for Women’s Disorders, Revenues by Product Segment 2006-2013
• Figure 9-1: The World Market for Women’s Disorders, Revenues by Product Segment 2006-2013

CHAPTER TEN: CORPORATE PROFILES AND ANALYSIS

• Table 10-1: The World Market for Women’s Disorders, Revenues and Market Share by Supplier 2008
• Figure 10-2: The World Market for Women’s Disorders, Top Ten Suppliers by Percent, 2008

Other users found this report page using the following search terms: Womens health female health Autoimmune diseases Cancer Gynecological and Sexually Transmitted Diseases Hormones Osteoporosis Urinary Disorders market 2009 worldwide world prevalence womens health prescription drug osteoporosis

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.